X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adamantane - analogs & derivatives (398) 398
humans (349) 349
index medicus (305) 305
animals (218) 218
male (188) 188
adamantane - pharmacokinetics (179) 179
pharmacology & pharmacy (173) 173
adamantane - pharmacology (165) 165
adamantane - therapeutic use (137) 137
diabetes mellitus, type 2 - drug therapy (136) 136
female (125) 125
adamantane - administration & dosage (101) 101
mice (96) 96
pharmacokinetics (92) 92
rats (92) 92
vildagliptin (86) 86
adamantane - chemistry (84) 84
type 2 diabetes (84) 84
adult (80) 80
adamantane - adverse effects (78) 78
dipeptidyl-peptidase iv inhibitors - therapeutic use (74) 74
hypoglycemic agents - therapeutic use (74) 74
middle aged (74) 74
chemistry, medicinal (68) 68
administration, oral (64) 64
treatment outcome (60) 60
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (58) 58
glucagon-like peptide-1 (57) 57
pyrrolidines - pharmacokinetics (55) 55
pyrrolidines - therapeutic use (55) 55
diabetes (54) 54
dipeptidyl-peptidase iv inhibitors - pharmacology (54) 54
nitriles - pharmacokinetics (54) 54
drug therapy, combination (53) 53
nitriles - therapeutic use (53) 53
improves glycemic control (52) 52
saxagliptin (52) 52
biochemistry & molecular biology (50) 50
endocrinology & metabolism (50) 50
pyrrolidines - pharmacology (49) 49
structure-activity relationship (48) 48
analysis (47) 47
dose-response relationship, drug (46) 46
nitriles - pharmacology (46) 46
dipeptides - therapeutic use (45) 45
hypoglycemic agents - pharmacokinetics (45) 45
nitriles - administration & dosage (45) 45
pyrrolidines - administration & dosage (45) 45
research (45) 45
aged (44) 44
double-blind (44) 44
hypoglycemic agents - adverse effects (44) 44
beta-cell function (43) 43
drug therapy (43) 43
hypoglycemic agents - administration & dosage (39) 39
adamantane - chemical synthesis (38) 38
diabetes mellitus, type 2 - blood (38) 38
glucose (38) 38
metformin (38) 38
nitriles - adverse effects (38) 38
pyrrolidines - adverse effects (38) 38
sitagliptin phosphate (38) 38
hypoglycemic agents - pharmacology (37) 37
pharmacology/toxicology (37) 37
article (36) 36
chemistry, organic (36) 36
dipeptidyl-peptidase iv inhibitors - adverse effects (36) 36
sitagliptin (36) 36
care and treatment (35) 35
dipeptides - pharmacokinetics (35) 35
safety (35) 35
dosage and administration (34) 34
efficacy (34) 34
internal medicine (34) 34
adamantane - metabolism (33) 33
dipeptidyl-peptidase iv inhibitors - administration & dosage (33) 33
drug interactions (33) 33
type-2 diabetes-mellitus (33) 33
adamantane (32) 32
hypoglycemic agents (32) 32
in-vitro (32) 32
medicine & public health (32) 32
blood glucose - drug effects (31) 31
blood glucose - metabolism (31) 31
adamantane - blood (30) 30
cross-over studies (30) 30
drugs (30) 30
half-life (30) 30
molecular structure (30) 30
young adult (30) 30
area under curve (29) 29
drug-naive patients (29) 29
insulin (29) 29
dipeptides - adverse effects (28) 28
dipeptidyl peptidase-4 inhibitor (28) 28
dpp-4 inhibitor (28) 28
enzyme inhibitors - pharmacology (28) 28
glycemic control (28) 28
dipeptidyl peptidase 4 - metabolism (27) 27
dipeptides - pharmacology (26) 26
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2010, Volume 12, Issue 8, pp. 648 - 658
Type 2 diabetes (T2DM) is a complex disease combining defects in insulin secretion and insulin action. New compounds have been developed for improving... 
DPP‐4 inhibitor | linagliptin | sitagliptin | vildagliptin | alogliptin | pharmacokinetics | type 2 diabetes mellitus | saxagliptin | DPP-4 inhibitor | Alogliptin | Sitagliptin | Linagliptin | Vildagliptin | Type 2 diabetes mellitus | Pharmacokinetics | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | RECEPTOR AGONISTS | SINGLE-DOSE PHARMACOKINETICS | RENAL IMPAIRMENT | ORAL ANTIDIABETIC AGENTS | HEALTHY MALE-VOLUNTEERS | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | HEPATIC IMPAIRMENT | TYPE-2 DIABETES-MELLITUS | Dipeptides - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Half-Life | Male | Pyrazines - therapeutic use | Nitriles - pharmacokinetics | Pyrrolidines - therapeutic use | Drug Interactions | Adamantane - therapeutic use | Female | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Adamantane - pharmacokinetics | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Dipeptides - therapeutic use | Pyrrolidines - pharmacokinetics | Randomized Controlled Trials as Topic | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Pyrazines - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Type 2 diabetes | Physiological aspects | Glucose | Metabolites | Dextrose | Cytochrome P-450
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 3/2012, Volume 51, Issue 3, pp. 147 - 162
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 2, pp. 153 - 157
Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide, lixisenatide) have recently been used as anti-diabetes drugs. We examined... 
pharmacokinetics | dipeptidyl peptidase-4 inhibitor | glucagon-like peptide-1 receptor agonist | target molecular binding occupancy | pharmacodynamics | Dipeptidyl peptidase-4 inhibitor | Pharmacodynamics | Pharmacokinetics | Glucagon-like peptide-1 receptor agonist | Target molecular binding occupancy | GLUCAGON-LIKE PEPTIDE-1 | PHARMACOLOGY & PHARMACY | PROMOTES SATIETY | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Peptides - pharmacokinetics | Nitriles - pharmacokinetics | Peptides - administration & dosage | Peptides - metabolism | Hypoglycemic Agents - administration & dosage | Pyrrolidines - metabolism | Adamantane - therapeutic use | Adamantane - administration & dosage | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Hyperglycemia - prevention & control | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Piperidines - metabolism | Pyrrolidines - pharmacokinetics | Adamantane - metabolism | Models, Molecular | Uracil - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Liraglutide - therapeutic use | Venoms - therapeutic use | Ligands | Venoms - metabolism | Sitagliptin Phosphate - pharmacokinetics | Venoms - pharmacokinetics | Nitriles - therapeutic use | Liraglutide - metabolism | Sitagliptin Phosphate - metabolism | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Molecular Targeted Therapy | Pyrrolidines - therapeutic use | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Liraglutide - pharmacokinetics | Uracil - administration & dosage | Venoms - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - metabolism | Piperidines - pharmacokinetics | Adamantane - pharmacokinetics | Nitriles - metabolism | Reproducibility of Results | Diabetes Mellitus, Type 2 - blood | Algorithms | Piperidines - therapeutic use | Sitagliptin Phosphate - therapeutic use | Uracil - metabolism | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Uracil - pharmacokinetics | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - therapeutic use | Uracil - analogs & derivatives | Binding | Drugs | Effectiveness | Peptidase | Glucagon | Diabetes mellitus | Theoretical analysis | Low level | Receptors | Inhibitors | Nitric oxide | Occupancy | Hemoglobin | Agonists | Glucagon-like peptide 1 | Drug dosages
Journal Article
Journal Article
Journal of Pharmacy and Pharmaceutical Sciences, ISSN 1482-1826, 09/2015, Volume 18, Issue 3, pp. 434 - 447
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2014, Volume 16, Issue 10, pp. 891 - 899
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 4/2011, Volume 50, Issue 4, pp. 253 - 265
Patients with type 2 diabetes mellitus often have impaired renal function or may have impaired hepatic function, which can pose significant safety and... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Research-and-development | Antihyperglycaemics, pharmacokinetics | Type-2-diabetes-mellitus | Diabetes-mellitus | Dipeptides, pharmacokinetics | Renal-impairment | Saxagliptin, pharmacokinetics | Haemodialysis | Liver-dysfunction | METFORMIN | THERAPY | CHRONIC LIVER-DISEASE | SAFETY | IMPROVES GLYCEMIC CONTROL | RISK | PHARMACOLOGY & PHARMACY | RANDOMIZED CONTROLLED-TRIAL | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Hepatic Insufficiency - urine | Dipeptides - pharmacokinetics | Humans | Middle Aged | Hypoglycemic Agents - analysis | Half-Life | Dipeptides - urine | Male | Metabolic Clearance Rate | Adamantane - urine | Adamantane - analysis | Adamantane - blood | Adult | Dipeptidyl-Peptidase IV Inhibitors - analysis | Female | Renal Insufficiency - blood | Hepatic Insufficiency - metabolism | Adamantane - pharmacokinetics | Adamantane - adverse effects | Adamantane - analogs & derivatives | Severity of Illness Index | Hypoglycemic Agents - pharmacokinetics | Dialysis Solutions - chemistry | Dipeptides - adverse effects | Dipeptides - analysis | Renal Insufficiency - metabolism | Renal Insufficiency - urine | Hepatic Insufficiency - blood | Kidney Failure, Chronic - metabolism | Kidney Failure, Chronic - therapy | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Kidney Failure, Chronic - blood | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Dipeptides - blood | Renal Dialysis | Complications and side effects | Liver diseases | Physiological aspects | Dosage and administration | Research | Pharmacokinetics | Saxagliptin
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2012, Volume 7, Issue 1, p. e30479
There presently is no rapid method to assess the bactericidal activity of new regimens for tuberculosis. This study examined PNU-100480, TMC207, PA-824, SQ109,... 
MYCOBACTERIUM-TUBERCULOSIS | MURINE MODEL | IMMUNITY | MULTIDRUG-RESISTANT | DIARYLQUINOLINE TMC207 | BACTERICIDAL ACTIVITY | PHARMACOKINETICS | TOLERANCE | MULTIDISCIPLINARY SCIENCES | Humans | Drug Monitoring - methods | Mycobacterium tuberculosis - drug effects | Quinolines - pharmacology | Oxazolidinones - therapeutic use | Quinolines - pharmacokinetics | Pyrazinamide - pharmacology | Nitroimidazoles - therapeutic use | Extensively Drug-Resistant Tuberculosis - blood | Time Factors | Adamantane - therapeutic use | Drug Therapy, Combination | Adamantane - pharmacokinetics | Nitroimidazoles - pharmacokinetics | Adamantane - analogs & derivatives | Antitubercular Agents - therapeutic use | Extensively Drug-Resistant Tuberculosis - drug therapy | Adamantane - pharmacology | Reproducibility of Results | Nitroimidazoles - pharmacology | Oxazolidinones - pharmacokinetics | Pyrazinamide - pharmacokinetics | Antitubercular Agents - pharmacology | Ethylenediamines - pharmacokinetics | Ethylenediamines - pharmacology | Ethylenediamines - therapeutic use | Pyrazinamide - therapeutic use | Antitubercular Agents - pharmacokinetics | Oxazolidinones - pharmacology | Diarylquinolines | Quinolines - therapeutic use | Microbial Sensitivity Tests - methods | Mycobacterium tuberculosis - growth & development | Tuberculosis | Vitamin D | Calcifediol | Alfacalcidol | Drug therapy, Combination | Pyrazinamide | Comparative analysis | Health aspects | Drugs | Blood & organ donations | BCG | Antimicrobial agents | Cultures | Pharmacology | Blood | Bactericidal activity | Multidrug resistant organisms | Endocarditis | Expected values | Blood culture
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 01/2008, Volume 48, Issue 1, pp. 85 - 95
We conducted 3 open–label, multiple–dose, 3‐period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction... 
type 2 diabetes | vildagliptin | calcium channel blocker | Dipeptidyl peptidase IV inhibitor | angiotensin converting enzyme inhibitor | pharmacokinetics | angiotensin receptor blocker | Type 2 diabetes | Angiotensin converting enzyme inhibitor | Calcium channel blocker | Vildagliptin | Angiotensin receptor blocker | Pharmacokinetics | LAF237 | RISK | PHARMACODYNAMICS | BLOOD-PRESSURE | DIABETES-MELLITUS | BIOTRANSFORMATION | MEN | PHARMACOLOGY & PHARMACY | HYPERTENSION | TYPE-2 | STAGE RENAL-DISEASE | dipeptidyl peptidase IV inhibitor | Nausea - chemically induced | Tablets | Humans | Middle Aged | Half-Life | Pyrrolidines - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Nitriles - pharmacokinetics | Ramipril - administration & dosage | Drug Interactions | Tetrazoles - administration & dosage | Ramipril - analogs & derivatives | Adamantane - administration & dosage | Ramipril - adverse effects | Amlodipine - administration & dosage | Adamantane - analogs & derivatives | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Administration, Oral | Pyrrolidines - pharmacokinetics | Amlodipine - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Cross-Over Studies | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Valine - adverse effects | Nitriles - adverse effects | Tetrazoles - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - adverse effects | Valsartan | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Antihypertensive Agents - administration & dosage | Pyrrolidines - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics | Valine - administration & dosage | Nitriles - administration & dosage | Amlodipine - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Headache - chemically induced | Adamantane - pharmacokinetics | Adamantane - adverse effects | Valine - pharmacokinetics | Valine - analogs & derivatives | Ramipril - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Tetrazoles - adverse effects | Amlodipine | Dosage and administration | Enzyme inhibitors | Research
Journal Article